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Abstract Hashimoto’s encephalopathy (HE) is a rare autoim-
mune disease associated with Hashimoto’s thyroiditis (HT). To
identify the HE-related autoantigens, we developed a human
brain proteome map using two-dimensional electrophoresis and
applied it to the immuno-screening of brain proteins that react
with autoantibodies in HE patients. After sequential MALDI-
TOF-MASS analysis, immuno-positive spots of 48 kDa (pI 7.3^
7.8) detected from HE patient sera were identi¢ed as a novel
autoimmuno-antigen, K-enolase, harboring several modi¢ca-
tions. Speci¢c high reactivities against human K-enolase were
signi¢cant in HE patients with excellent corticosteroid sensitiv-
ity, whereas the patients with fair or poor sensitivity to the
corticosteroid treatment showed less reactivities than cut-o¡
level. Although a few HT patients showed faint reactions to
K-enolase, 95% of HT patients, patients with other neurological
disorders, and healthy subjects tested were all negative. These
results suggest that the detection of anti-K-enolase antibody is
useful for de¢ning HE-related pathology, and this proteomic
strategy is a powerful method for identifying autoantigens of
various central nervous system diseases with unknown autoim-
mune etiologies. 5 2002 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
Key words: K-enolase; Autoantigen; Proteomics;
Two-dimensional electrophoresis ; Brain
1. Introduction
Hashimoto’s encephalopathy (HE) is a rare encephalopathy
associated with autoimmune Hashimoto’s thyroiditis (HT) [1].
To date only less than 40 cases of HE have been documented
in the literature since the ¢rst report in 1966 [2,3]. It initially
shows acute or sub-acute onset followed by relapsing-remit-
ting courses, but eventually develops a severe dementia like
Alzheimer’s disease. As HE responds well to corticosteroids in
early stage, its proper early diagnosis is critically important.
The presence of anti-thyroid antibodies is suggestive for HE
as well as HT; there are, however, no speci¢c clinico-labora-
tory tests for de¢ning HE-pathology, thus the HE patients
have been found with very low frequency.
To analyze the clinical features of HE precisely, we have
collected HE-like patients’ data from several areas in Japan
since 1992. To date, ¢ve patients are de¢ned as HE, almost
ful¢lling the clinical Peschen^Rosin’s criteria [3]. Although the
mechanism of HE remains unclear, several lines of evidence
suggest an autoimmune etiology of HE [4,5]. The presence of
autoantibodies in patients is one of hallmarks of autoimmun-
ity, yet identi¢cation of HE-relevant autoantigens in the cen-
tral nervous system (CNS) has never been reported. Although
the humoral immune response of HE patients has been ana-
lyzed by the serological analysis of a brain-derived cDNA
expression library (SEREX) [6], this approach has not yet
yielded any HE-relevant autoantigens.
Recently, we developed a mouse brain proteome map and
applied it to the pathological study of brain diseases [7]. This
strategy was thought to be applicable to the screening of
autoantigens in human CNS diseases with autoimmune etiol-
ogies by using a human brain map. Thus we have newly
developed a proteomic screening system for identifying any
autoantigens by creating a human brain protein map of
two-dimensional gel electrophoresis (2-DE), a sequential
Western immunoblotting system with patient’s sera, and sub-
sequent sensitive methods for the identi¢cation of target spots
by high-throughput matrix-assisted laser desorption ionization
time-of-£ight (MALDI-TOF) mass spectrometric analysis. By
using this system, proteins immuno-reactive to the HE pa-
tients’ sera were successfully identi¢ed as human K-enolase
harboring various modi¢ed structures, and the high speci¢city
was con¢rmed using a variety of control patients including
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HT and normal subjects. The possible relation between this
autoantigen and an HE-etiology as well as the validity of
screening using the brain proteomic strategy is discussed.
2. Materials and methods
2.1. Subjects
Sera from ¢ve patients with clinically diagnosed HE were studied.
All had a corticosteroids-responsive reversible encephalopathy associ-
ated with euthyroid HT [8], and exhaustive exclusions of other causes
of encephalopathy had been carried out. Four female patients (pa-
tients 1, 2, 3 and 4) had clinically de¢nite HE with multiphasic courses
according to Peschen^Rosin’s criteria [3]. Patients 1, 2 and 3 showed
excellent responses to corticosteroids, while patient 4 showed a fair
response. The male patient (patient 5), because of a monophasic
course, possibly had HE showing a poor corticosteroids response.
All serum samples were from patients with an active, untreated dis-
ease. Apart from HT, none of the HE patients had other autoimmune
diseases. Sera from 25 healthy subjects (HC), 54 patients with HT
without encephalopathy and 20 patients with other neurological dis-
orders (OND; 10 with encephalitis, 5 with neurodegenerative disor-
der, 4 with multiple sclerosis and one with acute disseminated ence-
phalomyelitis) were used as controls.
2.2. Preparation of tissue proteins
Human parietal lobe tissues of cerebrum were obtained from a
68-year-old man who died of pneumonia and underwent an autopsy
6 h postmortem. He had no neurological diseases and there were no
abnormalities found upon routine brain examination. Brain tissue
(250 mg wet weight) was homogenized with 800 Wl of a lysis solution,
consisting of 9.8 M urea, 2% w/v NP-40, 2% v/v Pharmalyte, 100 mM
DTT, 0.5 Wg/ml E-64, 0.5 mM PMSF, 40 Wg/ml TLCK, 1 Wg/ml
aprotinin, 10 Wg/ml chymostatin, 0.5 mM EDTA, and 0.01% w/v
bromophenol blue (BPB). The protein concentration was determined
in the lysis solution with a dye reagent from Bio-Rad Laboratories
(Richmond, CA, USA) using BSA as a standard, and adjusted to
140 Wg/ml (50 Wg protein per gel) for silver staining, and to 1.4 mg/
ml (500 Wg protein per gel) for protein identi¢cation. An aliquot of
350 Wl was mixed with the internal marker proteins and subjected to
2-DE.
2.3. Two-dimensional electrophoresis (2-DE)
2-DE was carried out in a horizontal electrophoresis system, Mal-
tiphor II (Amersham Pharmacia), for the ¢rst-dimensional isoelectric
focusing using Immobiline dry strip (18-cm long for large gels and
7-cm for mini gels, linear gradient between pH 3^10, Amersham Phar-
macia), and by a Giant slab gel electrophoresis system (Nihon-Eido,
Tokyo, Japan) for the second-dimensional SDS^PAGE (12.0% gel).
The ¢rst-dimensional immobilized pH gradient (IPG) on the rehy-
drated gel strip was carried out according to the manufacturer’s in-
structions. After the ¢rst dimension, the IPG gel was equilibrated with
equilibration bu¡er consisting of 50 mM Tris^HCl (pH 6.8), 6 M
Urea, 3% SDS, 50 mM DTT and 0.01% BPB, and subjected to the
second-dimensional SDS^PAGE (20U20U0.1 cm for large gels, and
8U10U0.1 cm for mini gels).
2.4. Western blotting and computer graphic analysis
The protein spots on the gels were electroblotted onto a polyviny-
lidene di£uoride (PVDF) membrane (Fluortrans1, Pall Ultra¢ne Fil-
tration, CA, USA) with a semi-dry blotting apparatus (Nihon-Eido,
Tokyo, Japan) at 0.5 mA/cm2 for 3 h at 4‡C. The blotting bu¡er for
amino acid sequencing of the PVDF membrane consisted of 10 mM
CAPS-NaOH (pH 11.0) and 10% methanol. The PVDF membrane
was stained with 0.1% Coomassie Brilliant Blue (CBB) in 50% meth-
anol or with the £uorescent SYPRO ruby protein blot stain reagent
(Bio-Rad). The stained gels and PVDF membranes were scanned and
analyzed using Image Reader Ver. 1.3 and Mac Bas V2.5 (Fuji Photo
Film), and analyzed using PDQUEST1 software.
2.5. Peptide mass ¢ngerprinting and protein sequencing
Brain proteins separated on the 2-DE-gel were stained with CBB or
£uorescent reagent for polyacrylamide gel (SYPRO ruby gel stain,
Bio-Rad). The protein spots detected to be immuno-reactive with
patient’s sera were cut and sliced into small pieces. The gels were
then subjected to reduced-S-pyrydilethylation, dehydrated in 100%
acetonitrile, dried in a Speed-Vac, and soaked again with digestion
bu¡er containing trypsin. After the overnight protein digestion, pep-
tide fragments in the supernatant were desalted by Zip tips C18 (Milli-
pore, Bedford, MA, USA) and subjected to MALDI-TOF mass spec-
trometry (MALDI-TOF, Micro Mass, London, UK) for peptide mass
¢ngerprinting (PMF). The background noise was removed by subtrac-
tion of mass signals obtained from a control gel. Protein identi¢cation
was carried out using the MS-¢t search engine in ProteinProspector
(UCSF) by sending a query of the subtracted PMF data [9]. For the
N-terminal sequence, the stained protein spot on the PVDF mem-
brane was cut out and transferred into the cartridge of the Procise1
494cLC sequence system (Applied Biosystems, Foster City, CA,
USA). The amino acid sequence obtained from the analysis was sub-
jected to a search for sequence similarity against the PIR International
Database and/or SWISS-PROT [7].
2.6. Detection of anti-human K-enolase antibodies in patients’ sera
6UHis-recombinant human K-enolase expression vector, pQE-hE-
NOK [10] was expressed in Escherichia coli XL1-Blue strain and par-
tially puri¢ed by a Ni-NTA super-£ow a⁄nity column (Qiagen,
Chatsworth, CA, USA). Rabbit L-enolase (Sigma, St. Louis, MO,
USA), human Q-enolase (Polysciences, Warrington, PA, USA), and
the puri¢ed recombinant human K-enolase were run on 10% SDS^
PAGE gel, transferred onto PVDF membrane, and probed with sera
samples. Goat anti-human K-enolase antibody (Santa Cruz Biotech-
nology, CA, USA) was used as a positive control. The second anti-
body was horseradish peroxidase-conjugated sheep anti-human IgG
(Amersham Pharmacia) or horse anti-goat IgG (VECTOR Laborato-
ries, Burlingame, CA, USA), and bound conjugate was detected by
enhanced chemiluminescence.
Table 1
Mass-¢t analysis for tryptic fragments of spot 1-1
Signal
no.
m/zþ submitted NHþ matched Delta Da Start^end amino
acid no.
Peptide sequences Modi¢cations
1 1143.9333 1143.6156 0.3171 183^192 (R)IGAEVYHNLK(N)
2 1426.1017 1425.7260 0.3751 269^280 (R)YISPDQLADLYK(S)
3 1526.1854 1525.7692 0.4156 358^371 (K)LAQANGWGVMVSHR(S)
4 1541.1962 1540.7834 0.4128 239^252 (K)VVIGMDVAASEFFR(S)
5 1557.1670 1540.7834 0.3887 239^252 (K)VVIGMDVAASEFFR(S) Met-Oxidized
6 1682.2870 1681.8583 0.4287 345^359 (K)VNQIGSVTESLQACK(L)
7 1908.4705 1907.9870 0.4829 162^178 (K)LAMQEFMILPVGAANFR(E)
8 1924.4503 1907.9870 0.4678 162^178 (K)LAMQEFMILPVGAANFR(E) Met-Oxidized
9 1940.4369 1907.9870 0.4594 162^178 (K)LAMQEFMILPVGAANFR(E) 2Met-Oxidized
10 2033.5356 2033.0549 0.4801 306^325 (K)FTASAGIQVVGDDLTVTNPK(R)
Selected mass signals for tryptic peptides of spot 1-1 by MALDI-TOF-Mass analysis were completely matched (100%; 10/10) for the database
sequence of tryptic fragments of human K-enolase with a high MOWSE Score (6.93e+007). The peptide sequences shown in the table were ob-
tained from database sequences of K-enolase, of which peptide masses were matched to the search query of tryptic peptide-mass ¢ngerprinting.
The expected amino acid to be followed to the N-terminal or C-terminal sequence of each identi¢ed peptide is listed in parentheses. The MS-¢t
analysis for spots 1-2, and 1-3 (data not shown) also showed the same results as those for 1-1. The results of each spot were reproduced in the
three independent analyses. Representative data of 1-1 are shown in this table.
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Fig. 1. A: 2-DE pattern of human brain proteins, and detection of immuno-reactive proteins against autoantibodies of HE patients by immu-
noblotting. The brain proteins on 2-DE-gel were stained with £uorescent protein staining reagent (a), and the immuno-positive proteins on the
PVDF membrane were detected by immunoblotting with sera from HE patient 1 (b). The speci¢c spots 1-1, 1-2 and 1-3 reactive to the autoan-
tibody from the HE patient’s sera and a negative control 1-0 on 2-DE-gel are indicated with arrowheads. B: MALDI-TOF mass spectra of im-
muno-reactive spots 1-1, 1-2, 1-3 and control spot 1-0. The immuno-reactive spots (1-1, 1-2, 1-3) and negative control gel (1-0) were excised, di-
gested with trypsin, and subjected to MALDI-TOF mass analysis. Ten common signals of mono-isotopic peptides (m/z 1143.9, 1426.1, 1526.1,
1541.1, 1557.1, 1682.2, 1908.4, 1924.4, 1940.4, 2033.5) are detected in all three spectra for spots 1-1, 1-2 and 1-3 after subtraction of noise
peaks that also exist in the tryptic digest of control spot 1-0. Mass-¢t search for PMF was performed using the ten signals.
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3. Results
3.1. Identi¢cation of brain proteins reacted with autoantibodies
in HE patients
To detect the brain proteins that react with autoantibodies
raised in HE patients, we ¢rst created a human brain 2-DE
map. Brain extracts were separated on 2-DE (pI 3^10, 12%
PAGE, 20U20 cm) and stained with £uorescent reagent (Fig.
1Aa) and then CBB. The protein spots on the 2-DE map were
counted up to 2580 and the major proteins assigned according
to the mouse brain map presented previously [7,11]. Aliquots
of the brain proteins were subjected to 2-DE and transferred
to PVDF membrane. Sera from HE patient 1 were reacted on
the membrane, and the brain proteins that reacted with the
patient’s IgG were screened. Three spots of 48-kDa proteins
with pI ranging from 7.3 to 7.8 were detected (Fig. 1Ab: 1-1,
1-2, 1-3), and all were subjected to MALDI-TOF mass spec-
trometric analysis. The signals derived from the contaminants
such as autolytic fragments of trypsin in the negative control
(1-0) were successfully subtracted as background noise from
those of the protein spots 1-1, 1-2 and 1-3. As shown in Table
1, all of the ten speci¢c signals (indicated by arrows in Fig.
1B) selected in the spectrometry of the tryptic peptide from
each protein (Fig. 1B: 1-1, 1-2, 1-3) were well matched with
the calculated masses of tryptic fragments of human K-eno-
lase, EC.4.2.1.11 (2-phospho-D-glycerate hydrolase; non-neu-
ronal enolase, NNE; phosphopyruvate hydratase; SWISS-
PROT Accession No. P06733). The MOWSE Scores of the
Mass-¢t analysis for 1-1, 1-2, and 1-3 vs. human K-enolase
were 6.93e+007, 1.098e+007, and 1.436e+006, respectively.
The tryptic fragments of 162^178 and 239^252 of the brain
K-enolase were included with the oxidation forms of 164/
168Met and 243Met, respectively. N-terminal amino acid
analysis of spots 1-1 and 1-2 revealed their N-termini Ser to
be blocked. Thus, we concluded that the proteins of 48 kDa
that reacted with HE patients’ sera were varied modi¢ed
forms of human K-enolase. The same results were obtained
in the experiment using another 2-DE map of human tempo-
ral lobe of cerebrum from another woman aged 64 years who
died of pneumonia (data not shown).
3.2. Immuno-reactivities against human K-enolase
Speci¢c positive signals against recombinant human K-eno-
lase were found by Western immunoblotting in serum samples
from 3 of the 5 (60%) patients with HE (Fig. 2A,B); i.e.
signi¢cant high immuno-reactivities were found in all of the
three patients with clinically de¢nite relapsing HE showing
excellent corticosteroid responses (patients 1^3), while neither
patient with clinically de¢nite relapsing HE showing a fair
corticosteroid response (patient 4) nor with monophasic pos-
sible HE showing a poor corticosteroid response (patient 5)
had more reactivities than cut-o¡ level against K-enolase (Fig.
2A). Fifty-one of the 54 HT (94.4%) patients without enceph-
alopathy showed negative reactivities, although three (5.6%)
of the HT patients showed faint immuno-reactivities (less than
1/20 intensity of HE patients 1^3) against K-enolase (Fig. 2A).
None of the 20 patients with OND (10 with encephalitis, 5
with neurodegenerative disorder, 4 with multiple sclerosis, and
one with acute disseminated encephalomyelitis) or the 25 HC
were positive (0%). The positive rates in HE were signi¢cantly
higher compared with those in HT without encephalopathy
(P=0.021), OND (P=0.026), and HC (P=0.012; Fig. 2B).
Additional immuno-positive reactivities against other proteins
with M.W. about 30 kDa, besides human K-enolase (48 kDa),
possibly derived from Escherichia coli XL1-Blue strain, were
detected in some serum samples from HE patients, HT pa-
tients, OND patients and HC (Fig. 2A). However, there were
no signi¢cant di¡erences in the frequency against the addi-
tional signals for 30 kDa among HE, HT, OND or HC.
3.3. Speci¢city of anti-human K-enolase antibody
Goat anti-human K-enolase antibody showed ¢ve immuno-
positive spots of 48-kDa brain proteins (Fig. 3A). Subsequent
sequence analysis of these spots revealed that the very acidic
one (pI 5), absent in the immunoblotting with the patient’s
sera, was Q-enolase, suggesting the cross reactivity of this anti-
body against Q-enolase of human brain. On the other hand,
Fig. 2. A: Immuno-reactivities against recombinant human K-eno-
lase. Partially puri¢ed bacterial 6UHis-recombinant human K-eno-
lase was separated on 10% SDS^PAGE, transferred on PVDF mem-
branes, and probed with goat anti-human K-enolase antibody
(upper panel; PC, positive control), or sera from HE patients 1, 2,
3, 4, and 5 (upper panel; lanes 1, 2, 3, 4 and 5) with a dilution of
1:200. Results of two representative HT (HT without encephalo-
pathy) patients (upper panel; one is positive, Pos; another is nega-
tive, Neg), one representative HC (upper panel; HC) and one repre-
sentative OND patient (upper panel; OND) are also shown. After
stripping, the membranes were re-probed with goat anti-human
K-enolase antibody (lower panel). B: The positive rates of anti-
K-enolase antibody. Immuno-reactivities against human K-enolase
were detected by Western blotting with sera samples from ¢ve pa-
tients with HE, 54 with HT (HT without encephalopathy), 20 with
OND (10 with encephalitis, ¢ve with neurodegenerative disorder,
four with multiple sclerosis and one with acute disseminated ence-
phalomyelitis) and 25 with HC. The vertical line shows the % ratio
of the sample numbers with positive immuno-reaction in all of the
sample numbers tested in each group. Fisher’s exact test was used
for statistical analysis.
FEBS 26516 11-9-02
H. Ochi et al./FEBS Letters 528 (2002) 197^202200
sera from three HE patients (patients 1, 2 and 3) reacted with
only the basic two or three spots of K-enolase but not with the
acidic one of Q-enolase (Fig. 3A). Furthermore, sera from
these patients reacted neither with rabbit L-enolase (human
K-enolase shares 85% amino acid identity to rabbit L-enolase)
nor human Q-enolase (Fig. 3B). These results suggest that
autoantibodies from HE patients react with the speci¢c epi-
tope structure of human K-enolase.
4. Discussion
This study, by developing a new screening system for the
autoantigen in human brain, is the ¢rst to identify K-enolase
as an autoantigen in HE that exists both in the thyroid gland
and in the brain. It is important that the autoantigen detected
in this screening system is highly relevant for HE. Only three
of the 54 patients with HT contained anti-K-enolase antibod-
ies with much weaker reactivities than those of immuno-pos-
itive HE patients. Anti-K-enolase antibody is thus considered
to be speci¢c for HE, especially for multiphasic HE, rather
than HT.
Enolase is a ubiquitous glycolytic enzyme highly conserved
through evolution [12]. It exists as three highly homologous
isozymes: K, L and Q ; isozyme K is found in most tissues,
Fig. 3. A: Characterization of immuno-reactivities of HE patients’ sera by 2-DE-immunoblotting. Human normal brain extracts were separated
on mini-scaled 2-DE, transferred on the PVDF membrane, and probed with sera samples from patients 1, 2 and 3 and a control subject (HC)
(left panels). Immuno-positive spots were visualized with enhanced chemiluminescence. After stripping, the membranes were re-probed with
goat anti-human K-enolase antibody (right panels). B: Immuno-reactivities of HE patients’ sera against K-, L- and Q-enolase isoforms. Recombi-
nant human K-enolase, rabbit L-enolase and human Q-enolase were separated on 10% SDS^PAGE gel, transferred onto the PVDF membrane,
and probed with HE patient sera containing anti-K-enolase antibodies with a dilution of 1:200. Representative data of HE patient 1 are shown.
Totally identical results were obtained from two other HE patients (patients 2 and 3).
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isozyme L in muscle, and isozyme Q is present mainly in ner-
vous tissue [13]. Despite about 83% homology between amino
acids among three isozymes [14], the antibodies in HE only
reacted with K-enolase. Furthermore, sera from HE patients
reacted with various modi¢ed forms of K-enolase, the results
suggesting that these antibodies may recognize unique struc-
tural epitopes on this protein. However, further biochemical
study will be needed regarding the speci¢c epitope structure of
K-enolase.
One possible mechanism of HE is autoimmune cerebral
vasculitis [15]. Discovery of an anti-K-enolase antibody in
HE further supports this notion, since this antibody was
found in various autoimmune vasculitic diseases such as sys-
temic lupus erythematosus with renal disease, anti-neurotro-
phil cytoplasmic antibody-associated vasculitis and rheuma-
toid arthritis [16]. Another theory holds that the anti-K-
enolase antibody may induce global cerebral hypoperfusion,
resulting in encephalopathy through a disruption of cerebral
microvasculatures, because K-enolase is highly expressed in
the endothelium [17]. These hypothetical roles might need
examination in animal models in which anti-K-enolase anti-
bodies have been actively induced or passively administrated.
Identi¢cation of relevant autoantigens by immuno-screen-
ing of a brain-derived cDNA library usually is exhaustive
work. The present study con¢rmed that two-dimensional im-
munoblotting of human brain proteins followed by mass spec-
trometric identi¢cation of target proteins is a powerful tool
for searching for unknown autoantigens in ill-de¢ned auto-
immune CNS diseases. As in whole brain extract more than
2500 proteins are identi¢able on 2-DE, this proteomic strategy
may be applicable to a wide variety of other autoimmune
CNS diseases.
In summary, we have identi¢ed K-enolase as a novel auto-
antigen for HE using a brain proteomic screening system.
Detection of the anti-K-enolase antibody in conjunction with
the anti-thyroid antibodies may help proper diagnose HE as
well as predict corticosteroids response.
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